2025
Significance of Coronary Artery Calcifications and Ischemic Electrocardiographic Changes Among Patients Undergoing Myocardial Perfusion Imaging
Kokkinidis D, Kyriakoulis I, Chui P, Agarwal R, Liu Y, Khera R, Sinusas A, Velazquez E, Miller E, Feher A. Significance of Coronary Artery Calcifications and Ischemic Electrocardiographic Changes Among Patients Undergoing Myocardial Perfusion Imaging. JACC Advances 2025, 4: 101618. PMID: 39983619, PMCID: PMC11891677, DOI: 10.1016/j.jacadv.2025.101618.Peer-Reviewed Original ResearchCoronary artery calcificationMyocardial perfusion imagingIschemic ECG changesLow event ratesECG changesNormal perfusionArtery calcificationPerfusion imagingSingle-photon emission computed tomography/computed tomographyStress ECGCAC evaluationPresence of coronary artery calcificationSuspected coronary artery diseaseMedian follow-upEvent ratesIschemic electrocardiographic changesAnalysis to patientsComposite endpoint rateCoronary artery diseaseTomography/computed tomographyPrognostic informationMACE rateFollow-upSubgroup analysisAdverse outcomes
2022
Coronary Orbital Atherectomy in Patients With Severe Aortic Stenosis.
Donatelle M, Agasthi P, Parise H, Igyarto Z, Martinsen B, Leon M, Beohar N. Coronary Orbital Atherectomy in Patients With Severe Aortic Stenosis. Journal Of Invasive Cardiology 2022, 34: e696-e700. PMID: 36200995, DOI: 10.25270/jic/22.00066.Peer-Reviewed Original ResearchConceptsSevere aortic stenosisNon-AS cohortAortic stenosisNon-AS patientsSuccessful stent placementOrbital atherectomyStent placementOA useHospital major adverse cardiovascular eventsSevere calcific coronary artery diseaseCalcific coronary artery diseaseConcomitant severe aortic stenosisMajor adverse cardiovascular eventsCoronary orbital atherectomyIdeal revascularization strategyAdverse cardiovascular eventsMount Sinai Medical CenterProspective randomized trialsGlomerular filtration rateCoronary artery diseaseSinai Medical CenterPaucity of dataAngiographic complicationsMACE rateCardiovascular eventsThe Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk
Smolderen KG, Heath K, Scherr T, Bauzon SR, Howell AN, Mena-Hurtado C. The Nevada peripheral artery disease screening effort in a Medicare Advantage population and subsequent mortality and major adverse cardiovascular event risk. Journal Of Vascular Surgery 2022, 75: 2054-2064.e3. PMID: 35181520, DOI: 10.1016/j.jvs.2022.01.134.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsPeripheral artery diseaseUnadjusted hazard ratioLower extremity peripheral artery diseaseHazard ratioMedicare Advantage beneficiariesCause mortalityElectronic medical recordsArtery diseaseMajor adverse cardiovascular event riskAdverse cardiovascular eventsAtherosclerotic risk factorsMedicare Advantage populationCardiovascular event riskAnnual health assessmentPrimary care providersPatients' electronic medical recordsRisk of mortalityScreening resultsPositive screening resultsMACE ratePAD screeningCardiovascular eventsMultivariable adjustmentScreening status
2021
Prognostic Value of Phase Analysis for Predicting Adverse Cardiac Events Beyond Conventional Single-Photon Emission Computed Tomography Variables: Results From the REFINE SPECT Registry
Kuronuma K, Miller RJH, Otaki Y, Van Kriekinge SD, Diniz MA, Sharir T, Hu LH, Gransar H, Liang JX, Parekh T, Kavanagh PB, Einstein AJ, Fish MB, Ruddy TD, Kaufmann PA, Sinusas AJ, Miller EJ, Bateman TM, Dorbala S, Di Carli M, Tamarappoo BK, Dey D, Berman DS, Slomka PJ. Prognostic Value of Phase Analysis for Predicting Adverse Cardiac Events Beyond Conventional Single-Photon Emission Computed Tomography Variables: Results From the REFINE SPECT Registry. Circulation Cardiovascular Imaging 2021, 14: e012386. PMID: 34281372, PMCID: PMC8978932, DOI: 10.1161/circimaging.120.012386.Peer-Reviewed Original ResearchMeSH KeywordsAgedCanadaCoronary CirculationDisease ProgressionFemaleHumansIncidenceIsraelMaleMiddle AgedMyocardial IschemiaMyocardial Perfusion ImagingPredictive Value of TestsPrognosisRegistriesRisk AssessmentRisk FactorsStroke VolumeTomography, Emission-Computed, Single-PhotonUnited StatesVentricular Function, LeftConceptsMajor adverse cardiac eventsVentricular ejection fractionTotal perfusion deficitSingle photon emissionAdverse cardiac eventsEjection fractionPerfusion deficitsCardiac eventsPrognostic valueTomography myocardial perfusion imagingVentricular ejection fraction assessmentHighest decile groupProportional hazards analysisTomography myocardial perfusionIndependent prognostic significanceIndependent prognostic valueLarge multinational registryEjection fraction assessmentMyocardial perfusion imagingREFINE SPECT registryAdditional radiation exposureConventional single-photon emissionMACE riskMACE rateMultinational registry
2020
Prognostically safe stress-only single-photon emission computed tomography myocardial perfusion imaging guided by machine learning: report from REFINE SPECT
Hu LH, Miller RJH, Sharir T, Commandeur F, Rios R, Einstein AJ, Fish MB, Ruddy TD, Kaufmann PA, Sinusas AJ, Miller EJ, Bateman TM, Dorbala S, Di Carli M, Liang JX, Eisenberg E, Dey D, Berman DS, Slomka PJ. Prognostically safe stress-only single-photon emission computed tomography myocardial perfusion imaging guided by machine learning: report from REFINE SPECT. European Heart Journal - Cardiovascular Imaging 2020, 22: 705-714. PMID: 32533137, DOI: 10.1093/ehjci/jeaa134.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsPhysician interpretationMACE rateCancellation rateTomography myocardial perfusion imagingAdverse cardiac eventsInternational multicentre registryCause mortality ratesMyocardial perfusion imagingCurrent clinical approachesSingle photon emissionMulticentre registryCardiac eventsClinical dataMortality ratePerfusion imagingClinical approachPatientsML thresholdsRadiation exposureMPI scansPhoton emissionML scoreMLSafety
2019
5-Year Prognostic Value of Quantitative Versus Visual MPI in Subtle Perfusion Defects Results From REFINE SPECT
Otaki Y, Betancur J, Sharir T, Hu LH, Gransar H, Liang JX, Azadani PN, Einstein AJ, Fish MB, Ruddy TD, Kaufmann PA, Sinusas AJ, Miller EJ, Bateman TM, Dorbala S, Di Carli M, Tamarappoo BK, Germano G, Dey D, Berman DS, Slomka PJ. 5-Year Prognostic Value of Quantitative Versus Visual MPI in Subtle Perfusion Defects Results From REFINE SPECT. JACC Cardiovascular Imaging 2019, 13: 774-785. PMID: 31202740, PMCID: PMC6899217, DOI: 10.1016/j.jcmg.2019.02.028.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsTotal perfusion deficitStress total perfusion deficitMACE rateHazard ratioRate of MACECox proportional hazards analysisTomography myocardial perfusion imagingAdjusted hazard ratioAdverse cardiac eventsNonfatal myocardial infarctionProportional hazards analysisMyocardial perfusion imagingSingle photon emissionCardiac eventsLate revascularizationUnstable anginaRisk stratificationPrognostic valueKaplan-MeierPerfusion abnormalitiesPerfusion deficitsMyocardial infarctionPrognostic studiesMyocardial perfusion
2015
Early and late clinical outcomes after saphenous vein graft treatment with MGuardTM stents vs. drug-eluting stents
da Silva D, da Costa J, de Castro Filho A, Staico R, Costa R, Moreira A, Siqueira D, Chamié D, Centemero M, Maldonado G, Cano M, Tanajura L, Chaves Á, Feres F, Abizaid A, Sousa A, Sousa J. Early and late clinical outcomes after saphenous vein graft treatment with MGuardTM stents vs. drug-eluting stents. Journal Of Transcatheter Interventions 2015, 23: 251-255. DOI: 10.1016/j.rbciev.2017.02.007.Peer-Reviewed Original ResearchSaphenous vein graftsPercutaneous coronary interventionTarget lesion revascularizationClinical outcomesLesion revascularizationClinical outcomes of patientsDES groupRate of target lesion revascularizationOutcomes of patientsCohort of patientsAdverse cardiovascular eventsSVG treatmentSaphenous vein graft lesionsTreated with DESProportion of womenEmbolization of fragmentsTertiary centerRetrospective studyMACE rateAngiographic successCardiovascular eventsLow incidencePeriprocedural infarctionCoronary interventionVein graftsA novel drug‐coated scoring balloon for the treatment of coronary in‐stent restenosis: Results from the multi‐center randomized controlled PATENT‐C first in human trial
Scheller B, Fontaine T, Mangner N, Hoffmann S, Bonaventura K, Clever Y, Chamie D, Costa R, Gershony G, Kelsch B, Kutschera M, Généreux P, Cremers B, Böhm M, Speck U, Abizaid A. A novel drug‐coated scoring balloon for the treatment of coronary in‐stent restenosis: Results from the multi‐center randomized controlled PATENT‐C first in human trial. Catheterization And Cardiovascular Interventions 2015, 88: 51-59. PMID: 26331782, DOI: 10.1002/ccd.26216.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryBrazilCardiac CathetersCardiovascular AgentsCoated Materials, BiocompatibleCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisFemaleGermanyHumansMaleMetalsMiddle AgedPaclitaxelPercutaneous Coronary InterventionRetreatmentStentsTime FactorsTomography, Optical CoherenceTreatment OutcomeConceptsTarget lesion revascularizationLate lumen lossIn-segment late lumen lossIn-stent restenosisSB groupScoring balloonBare metal stentsAngiographic in-segment late lumen lossCoronary bare metal stentTreatment of in-stent restenosisTreatment of coronary in-stent restenosisRate of binary restenosisCoronary in-stent restenosisAdverse cardiovascular eventsPresence of diabetesFollow-up quantitative coronary angiographyQuantitative coronary angiographyBlinded core labRandomized controlled trialsPrimary endpointSecondary endpointsCoronary angiographyMACE rateCardiovascular eventsLesion revascularization
2012
Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes
Marso SP, Mercado N, Maehara A, Weisz G, Mintz GS, McPherson J, Schiele F, Dudek D, Fahy M, Xu K, Lansky A, Templin B, Zhang Z, de Bruyne B, Serruys PW, Stone GW. Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or Diabetes. JACC Cardiovascular Imaging 2012, 5: s42-s52. PMID: 22421230, DOI: 10.1016/j.jcmg.2012.01.008.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngina, UnstableAngioplasty, Balloon, CoronaryChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary StenosisDiabetes MellitusEuropeFemaleHeart ArrestHumansKaplan-Meier EstimateMaleMetabolic SyndromeMiddle AgedMultivariate AnalysisMyocardial InfarctionNecrosisPlaque, AtheroscleroticPredictive Value of TestsProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTomography, X-Ray ComputedTreatment OutcomeUltrasonography, InterventionalUnited StatesVascular CalcificationConceptsMajor adverse cardiac eventsGreater necrotic coreUntreated nonculprit lesionsAcute coronary syndromeMet SynNonculprit lesionsPercutaneous coronary interventionSYN patientsNecrotic coreMACE rateMetabolic syndromePlaque burdenFuture major adverse cardiac eventsSubsequent major adverse cardiac eventsAcute coronary syndrome patientsSuccessful percutaneous coronary interventionGreater plaque burdenAdverse cardiac eventsCoronary syndrome patientsHigh-risk groupQuantitative coronary angiographySmaller lumen areaACS patientsCoronary syndromeACS population
2011
Comparação randomizada entre o stent eluidor de paclitaxel de nova geração sem polímero e o stent eluidor de paclitaxel com polímero durável em pacientes com doença arterial coronária: resultados da análise angiográfica e ultrassonográfica seriada do estudo PAX-A
Chamié D, Costa J, Abizaid A, Costa R, Feres F, Staico R, Siqueira D, Tanajura L, Abizaid A, Sousa A, Sousa J. Comparação randomizada entre o stent eluidor de paclitaxel de nova geração sem polímero e o stent eluidor de paclitaxel com polímero durável em pacientes com doença arterial coronária: resultados da análise angiográfica e ultrassonográfica seriada do estudo PAX-A. Journal Of Transcatheter Interventions 2011, 19: 379-391. DOI: 10.1590/s2179-83972011000400008.Peer-Reviewed Original ResearchIn-stent late luminal lossPaclitaxel-eluting stentsLate luminal lossFollow-upIn-stentEnd pointsObstruction volumeLuminal lossIntravascular ultrasoundSecondary end pointsPrimary end pointSingle-center studyAdverse cardiac eventsLocal vascular inflammationLong-term safetyNon-fatal MIFirst-generation drug-eluting stentsIncreased rates of late stent thrombosisRates of late stent thrombosisAngiographic characteristicsDrug-eluting stentsCardiac eventsMACE rateBinary restenosisVascular inflammationImpact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials
Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW. Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents Pooled Analysis From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovascular Interventions 2011, 4: 1209-1215. PMID: 22115661, DOI: 10.1016/j.jcin.2011.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsChi-Square DistributionCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSeverity of Illness IndexSirolimusThrombosisTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsPaclitaxel-eluting stentsReference vessel diameterEverolimus-eluting stentsPercutaneous coronary interventionLong lesionsGroup BLesion lengthMACE rateCoronary interventionSmall vesselsGroup AStent typeShort lesionsAdverse cardiac eventsHigh-risk patientsPatient-level dataLarge vesselsLower ratesCOMPARE trialLesion revascularizationEfficacy outcomesAdverse eventsCardiac eventsIndependent predictors
2005
Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction
Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation 2005, 111: 1611-1618. PMID: 15811868, DOI: 10.1161/01.cir.0000160362.55803.40.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrimary stentingAddition of abciximabBody surface areaCADILLAC trialMyocardial infarctionRisk factorsFemale genderIschemic target vessel revascularizationLower body surface areaMajor adverse cardiac eventsOverall adverse outcomesTIMI grade 3Adverse cardiac eventsTarget vessel revascularizationClinical risk factorsComorbid risk factorsInterventional treatment strategiesImportant independent determinantHigh mortality rateMACE ratePrimary angioplastyCardiac eventsSymptom onsetIndependent predictors
2003
Brachytherapy for in-stent restenosis in general interventional practice A single institution's experience using four radiation devices
Singh HS, Roberts KB, Yue N, Nath R, Song GH, Azimi N, Pfau S. Brachytherapy for in-stent restenosis in general interventional practice A single institution's experience using four radiation devices. Cardiovascular Revascularization Medicine 2003, 4: 126-132. PMID: 14984712, DOI: 10.1016/s1522-1865(03)00183-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBlood Vessel Prosthesis ImplantationBrachytherapyConnecticutCoronary AngiographyCoronary Artery BypassCoronary RestenosisCoronary StenosisEquipment DesignFamily PracticeFemaleFollow-Up StudiesHospital MortalityHumansMaleMiddle AgedRadiation DosageReoperationRetrospective StudiesStentsTreatment OutcomeConceptsMajor adverse cardiac eventsStent restenosisAverage treatment ageEffectiveness of brachytherapyAdverse cardiac eventsSingle institution experienceMinimal lumen diameterRandomized clinical trialsLesion-specific characteristicsSpectrum of patientsMACE rateHospital deathCardiac eventsRenal failureUnstable anginaClinical outcomesCoronary lesionsTreatment failureInstitution experienceFrequent presentationInterventional therapyClinical trialsGeneral populationInterventional practicePatients
2002
Device selection in the treatment of in-stent restenosis with and without radiation (from the Gamma Radiation Trials)
Ajani AE, Waksman R, Zimarino M, Kim H, Pichard AD, Satler LF, Kent KM, White RL, Pinnow E, Mehran R, Lansky A, Lindsay J. Device selection in the treatment of in-stent restenosis with and without radiation (from the Gamma Radiation Trials). The American Journal Of Cardiology 2002, 89: 137-144. PMID: 11792331, DOI: 10.1016/s0002-9149(01)02189-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceAngioplastyAngioplasty, Balloon, CoronaryChi-Square DistributionCoronary DiseaseDose-Response Relationship, RadiationFemaleHumansIridium RadioisotopesLogistic ModelsMaleMiddle AgedProspective StudiesRisk FactorsSecondary PreventionStentsTreatment OutcomeVascular PatencyConceptsExcimer laser coronary angioplastyMajor adverse coronary eventsAdditional stent implantationTreatment of ISRRecurrence rateCoronary angioplastyRotational atherectomyStent implantationStent restenosisBalloon percutaneous transluminal coronary angioplastyPercutaneous transluminal coronary angioplastyIntracoronary gamma radiationLate clinical outcomesAdverse coronary eventsOverall recurrence rateTransluminal coronary angioplastyLaser coronary angioplastyHigh recurrence rateUse of stentingDevice selectionAngiographic characteristicsMACE ratePlacebo groupPlacebo therapyCoronary events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply